MGO One Seven LLC Decreases Stake in Halozyme Therapeutics, Inc. $HALO

MGO One Seven LLC lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.5% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 7,100 shares of the biopharmaceutical company’s stock after selling 413 shares during the quarter. MGO One Seven LLC’s holdings in Halozyme Therapeutics were worth $369,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in HALO. GAMMA Investing LLC increased its holdings in Halozyme Therapeutics by 199.0% in the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company’s stock worth $179,000 after acquiring an additional 1,865 shares during the last quarter. QRG Capital Management Inc. bought a new position in Halozyme Therapeutics in the 1st quarter worth about $281,000. State of Alaska Department of Revenue boosted its stake in Halozyme Therapeutics by 0.8% in the 1st quarter. State of Alaska Department of Revenue now owns 46,903 shares of the biopharmaceutical company’s stock worth $2,991,000 after purchasing an additional 395 shares during the period. Cabot Wealth Management Inc. bought a new position in Halozyme Therapeutics in the 1st quarter worth about $207,000. Finally, Oppenheimer & Co. Inc. bought a new position in Halozyme Therapeutics in the 1st quarter worth about $625,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the subject of several analyst reports. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Morgan Stanley raised their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. JMP Securities raised their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. Finally, Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Five equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $73.00.

Insider Activity

In related news, CFO Nicole Labrosse sold 2,227 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer owned 22,079 shares in the company, valued at $1,721,058.05. The trade was a 9.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total value of $150,480.00. Following the completion of the sale, the director owned 44,952 shares of the company’s stock, valued at $3,382,188.48. The trade was a 4.26% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 108,227 shares of company stock worth $7,779,595. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $67.03 on Friday. The company has a market cap of $7.84 billion, a PE ratio of 15.34, a price-to-earnings-growth ratio of 0.36 and a beta of 1.16. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The stock has a 50-day moving average price of $71.56 and a 200-day moving average price of $62.09. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter last year, the company posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.